Unmet clinical needs in the use of zanubrutinib in malignant lymphomas (Waldenström macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma): A consensus-based position paper from an ad hoc expert panel.
Waldenström macroglobulinemia
mantle cell lymphoma
marginal zone lymphoma
zanubrutinib
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
21
04
2023
received:
10
02
2023
accepted:
25
04
2023
pubmed:
11
5
2023
medline:
11
5
2023
entrez:
11
5
2023
Statut:
ppublish
Résumé
Zanubrutinib has been approved for the treatment of patients with different lymphoproliferative disorders, and now represents a major breakthrough in the treatment of patients resistant or relapsing after the recommended therapies. Because few systematic studies or comparative randomized clinical trials have been conducted, optimal use of the drug in approved indications is challenging, and questions are emerging on its use in earlier stages of the disorders. This article presents the results of group discussion among an ad hoc constituted panel of experts aimed at identifying and addressing unmet clinical needs (UCNs) in the use of zanubrutinib in the lymphomas which have received the approval of use, specifically Waldenström macroglubulinemia, marginal zone lymphoma and mantle cell lymphoma. Key UCNs were selected according to the criterion of clinical relevance using the Delphi process. The panel produced recommendations and proposals for new studies for the management of the identified UCNs. These recommendations are intended for use not only by expert centers but above all by not experienced hematologists as well as general practitioners.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
795-808Informations de copyright
© 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
Références
Tam C, Grigg AP, Opat S, et al. The BTK inhibitor, BGB-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. Blood. 2015;126(23):832. https://doi.org/10.1182/blood.v126.23.832.832
Guo Y, Liu YE, Hu N, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase. J Med Chem. 2019;62(17):7923-7940. https://doi.org/10.1021/acs.jmedchem.9b00687
Delbecq AL, Van de Ven AH, Gustafson DH. Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes. Scott, Foresman and Co; 1975.
Swerdlow SH, Cook JR, Sohani AR, et al. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, eds. WHO classification of tumors of hematopoietic and lymphoid tissues. IARC; 2017:232-235.
Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367(9):826-833. https://doi.org/10.1056/nejmoa1200710
Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood. 2013;122(7):1222-1232. https://doi.org/10.1182/blood-2012-12-475111
Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637-1646. https://doi.org/10.1182/blood-2013-09-525808
Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenström’s macroglobulinemia: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2018;29(Suppl 4):iv41-iv50. https://doi.org/10.1093/annonc/mdy146
Castillo J, Advani RH, Branagan AR, et al. Consensus treatment WM 10th international workshop. Lancet Hematol. 2020;7(11):e827-e837. https://doi.org/10.1016/s2352-3026(20)30224-6
Treon SP, Xu L, Guerrera ML, et al. Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020;38(11):1198-1208. https://doi.org/10.1200/jco.19.02314
US FDA. FDA Approves Ibruitnib for Waldenstrom’s Macroglobulinemia; 2015. Accessed 8 November 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approveszanubrutinibwaldenstromsmacroglobulinemia.com
US FDA. FDA Approves Zanubrutinib for Waldenstrom’s Macroglobulinemia; 2021. Accessed 8 November 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approveszanubrutinibwaldenstromsmacroglobulinemia.com
NCCN Guidelines: Accessed 8 November 2022: Version 1.2023.
Treon SP, Meid K, Gustine J, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia. J Clin Oncol. 2021;39(6):565-575. https://doi.org/10.1200/jco.20.00555
Trotman J, Buske C, Tedeschi A, et al. Single-agent ibrutinib for rituximab-refractory Waldenström’s macroglobulinemia: final analysis of the substudy of the phase III iNNOVATETM trial. Clin Cancer Res. 2021;27(21):5793-5800. https://doi.org/10.1158/1078-0432.ccr-21-1497
Tam CS, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038-2050. https://doi.org/10.1182/blood.2020006844
Tam CS, Garcia-Sanz R, Opat S, et al. Long term follow-up results of a phase 3 randomized trial of zanubruitnib versus ibrutinib in patients with waldenstrom macroglobulinemia. J Clin Oncol. 2022;40(Suppl 16):7521. https://doi.org/10.1200/jco.2022.40.16_suppl.7521
Buske C, Tedeschi A, Trotman J, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström's macroglobulinemia: final analysis from the randomized phase III INNOVATE study. J Clin Oncol. 2022;40(1):52-62. https://doi.org/10.1200/jco.21.00838
Owen R, McCarthy H, Rule S, et al. Acalabrutinib in tratment-naïve or relapsed/refractory Waldenstrom Macroglobulinemia: 5 year follow-up of a phase 2 single arm study. Hemasphere. 2022;23(6):1020-1021. https://doi.org/10.1097/01.hs9.0000847388.33116.c7
Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027-2037. https://doi.org/10.1182/blood.2020006449
An G, Zhou D, Cheng S, et al. A phase II trial of the Bruton tyrosine-kinase inhibitor zanubrutinib (BGB-3111) in patients with relapsed/refractory waldenstrom macroglobulinemia. Clin Cancer Res. 2021;27(20):5490-5501. https://doi.org/10.1158/1078-0432.ccr-21-0539
Castillo JJ, Sarosiek SR, Gustine RJ, et al. Responses and survival predictors in a cohort of 319 patients with waldenstrom macroglobulinemia treated with ibruitnib monotherapy. Blood Adv. 2022;6(3):1015-1024. https://doi.org/10.1182/bloodadvances.2021006106
Castillo JJ, Meid K, Gustine JN, et al. Long-term follow-up of ibrutinib monotherapy in treatment naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022;36(2):532-539. https://doi.org/10.1038/s41375-021-01417-9
Owen RG, McCarthy H, Rule S, et Al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2021;8(4):e249.
Dimopoulos M, Sanz RG, Lee H.-P, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020;4(23):6009-6018. https://doi.org/10.1182/bloodadvances.2020003010
Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, et al. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018;132(24):2608-2612. https://doi.org/10.1182/blood-2018-07-863241
Rosenthal K, Abramson JS, Farrukh TA, et al. Management of BTK inhibitor associated adverse events: current practice trends among healthcare providers and concordance with expert recommendations. Blood. 2020;136(Suppl 1):5-6. https://doi.org/10.1182/blood-2020-139818
Rossi D, Bertoni F, Zucca E. Marginal-zone lymphomas. N Engl J Med. 2022;386(6):568-581. https://doi.org/10.1056/nejmra2102568
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC; 2017:263e265.
Salar A, Domingo-Domenech E, Panizo C, et al. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017;130(15):1772-1774. https://doi.org/10.1182/blood-2017-07-795302
Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009;145(6):741-748. https://doi.org/10.1111/j.1365-2141.2009.07677.x
Cervetti G, Galimberti S, Sordi E, et al. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010;21(4):851-854. https://doi.org/10.1093/annonc/mdp395
Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102(8):2741-2745. https://doi.org/10.1182/blood-2002-11-3496
Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116(1):106-114.
Orciuolo E, Buda G, Sordi E, et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res. 2010;34(2):184-189. https://doi.org/10.1016/j.leukres.2009.04.003
Raderer M, Wohrer S, Streubel B, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/ mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology. 2006;70(6):411-417. https://doi.org/10.1159/000098555
Rummel M, Kaiser U, Balser C, et al. Study Group Indolent Lymphomas. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open- label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57-66. https://doi.org/10.1016/s1470-2045(15)00447-7
Zucca E, Conconi A, Martinelli G, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35(17):1905-1912. https://doi.org/10.1200/jco.2016.70.6994
Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17-29. https://doi.org/10.1016/j.annonc.2019.10.010
Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224-2232. https://doi.org/10.1182/blood-2016-10-747345
Noy A, de Vos S, Coleman M, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. 2020;4(22):5773-5884. https://doi.org/10.1182/bloodadvances.2020003121
Opat S, Tedeschi A, Linton K, et al. The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma. Clin Cancer Res. 2021;27(23):6323-6332. https://doi.org/10.1158/1078-0432.ccr-21-1704
Strati P, Coleman M, Champion R, et al. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. Br J Haematol. 2022;199(1):76-85. https://doi.org/10.1111/bjh.18368
Armitage JO, Longo DL. Mantle-cell lymphoma. N Engl J Med. 2022;386(26):2495-2506. https://doi.org/10.1056/nejmra2202672
Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516. https://doi.org/10.1056/nejmoa1306220
Wang ML, Blum KA, Martin P, et al. Long term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739-745. https://doi.org/10.1182/blood-2015-03-635326
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. https://doi.org/10.1200/jco.2006.09.2403
Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770-778. https://doi.org/10.1016/s0140-6736(15)00667-4
Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018;32(8):1799-1803. https://doi.org/10.1038/s41375-018-0023-2
Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659-667. https://doi.org/10.1016/s0140-6736(17)33108-2
Wang M, Rule S, Zinzani PL, et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia. 2019;33(11):2762-2766. https://doi.org/10.1038/s41375-019-0575-9
Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851-859. https://doi.org/10.1182/blood.2019001160
Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021;5(12):2577-2585. https://doi.org/10.1182/bloodadvances.2020004074
Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory mantle cell lymphoma with zanubrutinib, a selective inhibitor of Bruton’s tyrosine kinase. Clin Cancer Res. 2020;26(16):4216-4224. https://doi.org/10.1158/1078-0432.ccr-19-3703
Song Y, Zhou K, Zou D, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139(21):3148-3158. https://doi.org/10.1182/blood.2021014162
Visco C, Di Rocco A, Evangelista A, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia. 2021;35(3):787-795. https://doi.org/10.1038/s41375-020-01013-3
Rusconi C, Cheah CY, Eyre TA, et al. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood. 2022;140(17):1907-1916. https://doi.org/10.1182/blood.2022015560
Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a singlecentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48-56. https://doi.org/10.1016/s1470-2045(15)00438-6
Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5(3):e109-e116. https://doi.org/10.1016/s2352-3026(18)30018-8
Wang M, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022;386(26):2482-2494. https://doi.org/10.1056/nejmoa2201817
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068. https://doi.org/10.1200/jco.2013.54.8800